

070050.2882  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Dillon  
Serial No. : 10/650,357 Examiner : Khanna, Hemant  
Filed : August 27, 2003 Group Art Unit: 1654  
For : METHODS AND COMPOSITIONS FOR PROTECTING AGAINST  
CATARACT DEVELOPMENT ASSOCIATED WITH VITRECTOMIES

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450.

Dec 8 2006

Date of Deposit

Lisa B. Krole  
Attorney Name  
[Signature]  
Signature

35,225

PTO Registration No.

Dec 8 2006  
Date of Signature

Commissioner for Patents  
Box 1450  
Alexandria, VA 22313-1450

Sir:

In supplement to the Information Disclosure Statement filed on May 11, 2004, and pursuant to the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicant respectfully requests that the publications relating to the above-identified application listed herein and on the accompanying PTO Form 1449, and not previously made of record, be considered by the Examiner and made of record in the United States Patent and Trademark Office.

12/12/2006 SDENB01 00000007 024377 10650357

02 FC:1806 180.00 DA

The documents listed below are also listed in the accompanying PTO Form 1449, which is submitted in duplicate.

1. Zest for Life specialized vitamin supplements, web site, 2006, Vitamin C-ascorbic acid-information. <http://www.wanyvitamins.com/vitamin-c-ascorbicacid-info.htm>.
2. United States Patent No. 6,949,241, issued September 27, 2005, by Molnarne-Kahan, entitled Use of lacrophyl preparation in eye drops containing therapeutically active compounds.
3. Dharmananda, 2004, Cataracts: prevention and treatment-with reference to Chinese medicin. Institutie for Traditional medicine, Portlan, Oregon.  
<http://www.itmonline.org/arts/cataracts.htm>.
4. Harocopos et al., 2004, Importance of vitreous liquefaction in age-related cataract, Invest Ophthalmol Vis Sci., 45(1):77-85.
5. Zhang et al., 2001, Microdialysis measurement of ascorbic acid in rabbit vitreous after photodynamic reaction, Exp. Eye Res. 73(3):303-309.
6. Takano et al., 1997, Determination of ascorbic acid in human vitreous humor by high-performance liquid chromatography with UV detection, Curr. Eye Res., 16(6):589-94.
7. Nishigori et al., 1985, Preventive effect of ascorbic acid against glucocorticoid-induced cataract formation of developing chick embryos, Exp. Eye Res., 40(3):445-451.
8. iHealthTree.com, website. VisiClear eye drops 4 packs from Trimedica.  
<http://www.ihealthtree.com/trimedica-visiclear-eyedrop-4packs.html>
9. Pfizer consumer health care, website. Visine Tears product description.  
<http://www.pfizerch.com/product.aspx?id=333>.


The submission of this Supplemental Information Disclosure Statement does not represent that a search has been made or that no better art exists and does not constitute an admission that any of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Please charge the fee under 37 C.F.R. 1.17(p) to Deposit Account No. 02-4377. Applicant believes that no fee in addition to the fee under 37 C.F.R. § 1.17(p) is due in connection with the filing of this Supplemental Information Disclosure Statement. However, if any additional fee is due, or overpayment made, with regard to this communication, the Commissioner is authorized to charge any such fee, and to credit any overpayment, to our Deposit Account No. 02-4377. A copy of this communication is enclosed


Respectfully submitted,

By:



Lisa B. Kole  
PTO Registration No. 35,225

Attorney for Applicant  
Baker Botts, LLP  
30 Rockefeller Plaza  
New York, NY 10112-4498  
(212) 408-2500



<b>Form PTO-1449 U.S. Department of Commerce</b> <b>(REV. 2-82) Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b>  <b>(Use several sheets if necessary)</b>	Atty. Docket No. 070050.2882	Serial No. 10/650,357
	Applicant Dillon	
	Filing Date August 27, 2003	Group 1654
	Examiner Khanna, Hemant	

U.S. PATENT DOCUMENTS								
*Exam. Initial.	No.		Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.
	2		6,949,241	September 27, 2005	Molnarne-Kahan			

FOREIGN PATENT DOCUMENTS								
Exam Initial	No.		Document No.	Date	Country	Class	Subclass	Translation Yes No

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	1	Zest for Life specialized vitamin supplements, web site, 2006, Vitamin C-ascorbic acid-information. <a href="http://www.vitamins.com/vitamin-c-ascorbicacid-info.htm">http://www.vitamins.com/vitamin-c-ascorbicacid-info.htm</a> .
	3	Dharmananda, 2004, Cataracts: prevention and treatment-with reference to Chinese medicin. Institutie for Traditional medicine, Portlan, Oregon. <a href="http://www.itmonline.org/arts/cataracts.htm">http://www.itmonline.org/arts/cataracts.htm</a> .

NY02:566158.1	
Examiner	Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No. 070050.2882	Serial No. 10/650,357
	Applicant Dillon	
	Filing Date August 27, 2003	Group 1654
	Examiner Khanna, Hemant	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	4	Harocopos et al., 2004, Importance of vitreous liquefaction in age-related cataract, Invest Ophthalmol Vis Sci., 45(1):77-85.
	5	Zhang et al., 2001, Microdialysis measurement of ascorbic acid in rabbit vitreous after photodynamic reaction, Exp. Eye Res. 73(3):303-309.
	6	Takano et al., 1997, Determination of ascorbic acid in human vitreous humor by high-performance liquid chromatography with UV detection, Curr. Eye Res., 16(6):589-94.
	7	Nishigori et al., 1985, Preventive effect of ascorbic acid against glucocorticoid-induced cataract formation of developing chick embryos, Exp. Eye Res., 40(3):445-451.
	8	iHealthTree.com, website. VisiClear eye drops 4 packs from Trimedica. <a href="http://www.ihealthtree.com/trimedica-visiclear-eyedrop-4packs.html">http://www.ihealthtree.com/trimedica-visiclear-eyedrop-4packs.html</a>
	9	Pfizer consumer health care, website. Visine Tears product description. <a href="http://www.pfizerch.com/product.aspx?id=333">http://www.pfizerch.com/product.aspx?id=333</a> .

NY02:566158.1	
Examiner	Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.